Anaplastic large cell lymphoma: Twenty-five years of discovery

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 1, 2011, Pages 19-43

  Kinney, Marsha C ^a   Higgins, Russell A ^a   Medina, Edward A ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HISTORY; HUMAN; LARGE CELL LYMPHOMA;

HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC;

EID: 79251624478     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (360)

1. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985; 66(4): 848-858.
2. Schwab U, Stein H, Gerdes ), et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 1982; 299 (5878): 65-67.
3. Kaneko Y, Frizzera G, Edamura S, et al. A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis. Blood. 1989; 73(3): 806-813.
4. Le Beau MM, Bitter MA, Larson RA, et al. The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1 -positive anaplastic large cell lymphoma. Leukemia. 1989; 3(12): 866-870.
5. Rimokh R, Magaud JP, Berger F, et al. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (Ki-1 lymphoma'). Br J Haematol. 1989; 71(1): 31-36.
6. Bitter MA, Franklin WA, Larson RA, et al. Morphology in Ki-1 (CD30)positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23;q35). Am J Surg Pathol. 1990; 14(4): 305-316.
7. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994; 263(5151): 1281-1284.
8. Pulford K, Lamant L, Morris SW, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997; 89(4): 1394-1404.
9. Shiota M, Fujimoto J, Takenaga M, et al. Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood. 1994; 84(11): 3648-3652.
10. Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood. 1995; 86(5): 1954-1960.
11. Kinney MC, Greer JP, Kadin ME, DeCouteau JF, Collins RD. p80npm/alk expression in Ki-1+ lymphomas: histologic and immunophenotypic correlation [abstract]. Lab Invest 1996; 74(1): 114A.
12. Falini B, Bigerna B, Fizzotti M, et al. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol. 1998; 153(3): 875-886.
13. Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999; 93(8): 2697-2706.
14. Cascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999; 93(11): 3913-3921.
15. Kinney MC, Collins RD, Greer JP, Whitlock JA, Sioutos N, Kadin ME. A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. Am J Surg Pathol. 1993; 17(9): 859-868.
16. Pileri S, Falini B, Delsol G, et al. Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1+ with a high content of reactive histiocytes). Histopathology. 1990; 16(4): 383-391.
17. Delsol G, Falini B, Muller-Hermelink HK, et al. Anaplastic large cell lymphoma (ALCL), ALK-positive. In: Swerdlow SH, Campo E, Harris NL et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008: 312-316.
18. Mason DY, Harris NL, Delsol G, et al. Anaplastic large cell lymphoma, ALK-negative. In: Swerdlow SH, Campo E, Harris NL, et al, eds. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008: 317-319.
19. World Health Organization Classification of Tumours; vol 3.
20. Ralfkiaer E, Willemze R, Pauli M, Kadin ME. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al, eds. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:300-301.
21. World Health Organization Classification of Tumours; vol 3.
22. Trumper L, Pfreundschuh M, Bonin FV, Daus H. Detection of the t(2;5)-associated NPM/ALK fusion cDNA in peripheral blood cells of healthy individuals. Br J Haematol. 1998; 103(4): 1138-1144.
23. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008; 111(12): 5496-5504.
24. Campo E, Chott A, Kinney MC, et al. Update on extranodal lymphomas: conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. Histopathology. 2006; 48(5): 481-504.
25. Eckerle S, Brune V, Doring C, et al. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia. 2009; 23(11): 2129-2138.
26. Piva R, Agnelli L, Pellegrino E, et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol. 2010; 28(9): 1583-1590.
27. Greer JP, Kinney MC, Collins RD, et al. Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma. J Clin Oncol. 1991; 9(4): 539-547.
28. Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005; 131(1): 39-49.
29. Le Deley MC, Reiter A, Williams D, et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood. 2008; 111 (3): 1560-1566.
30. d'Amore ES, Menin A, Bonoldi E, et al. Anaplastic large cell lymphomas: a study of 75 pediatric patients. Pediatr Dev Pathol. 2007; 10(3): 181-191.
31. Mann G, Attarbaschi A, Burkhardt B, et al. Clinical characteristics and treatment outcome of infants with non-Hodgkin lymphoma. Br J Haematol. 2007; 139(3):443-449.
32. Khor TS, Alessandri AJ, Jevon GP. Infant anaplastic large cell lymphoma with hemophagocytic syndrome. Pediatr Dev Pathol. 2010; 13(1): 72-76.
33. Bakshi NA, Ross CW, Finn WG, et al. ALK-positive anaplastic large cell lymphoma with primary bone involvement in children. Am J Clin Pathol. 2006; 125(1): 57-63.
34. Nagasaka T, Nakamura S, Medeiros LJ, Juco J, Lai R. Anaplastic large cell lymphomas presented as bone lesions: a clinicopathologic study of six cases and review of the literature. Mod Pathol. 2000; 13(10): 1143-1149.
35. Feldges A, Gerhard L, Reinhardt V, Budach V. Primary cerebral anaplastic T-cell-lymphoma (type Ki-1): review and case report. Clin Neuropathol. 1992; 11(2): 55-59.
36. Kodama K, Hokama M, Kawaguchi K, Tanaka Y, Hongo K. Primary ALK-1-negative anaplastic large cell lymphoma of the brain: case report and review of the literature. Neuropathology. 2009; 29(2): 166-171.
37. Carey MJ, Medeiros LJ, Roepke JE, Kjeldsberg CR, Elenitoba-Johnson KS. Primary anaplastic large cell lymphoma of the small intestine. Am J Clin Pathol. 1999; 112(5): 696-701.
38. Paulli M, Rosso R, Kindl S, et al. Primary gastric CD30 (Ki-1)-positive large cell non-Hodgkin's lymphomas: a clinicopathologic analysis of six cases. Cancer. 1994; 73(3): 541-549.
39. Ozkaynak MF. Favorable outcome of primary CNS anaplastic large cell lymphoma in an immunocompetent patient. J Pediatr Hematol Oncol. 2009; 31(2): 128-130.
40. Winter SS, Duncan MH, Foucar E, McConnell TS, Cartwright KC. Childhood Ki-1 lymphoma: presentation as a buttock mass. Am J Pediatr Hematol Oncol. 1991; 13(3): 334-337.
41. Driss M, Abbes I, Mrad K, et al. Primary CD30/ALK-1 positive anaplastic large cell lymphoma of the skeletal muscle in a child. Pathologica. 2009; 101 (2): 97-100.
42. Papadimitriou JC, Abruzzo LV, Bourquin PM, Drachenberg CB. Correlation of light microscopic, immunocytochemical and ultrastructural cytomorphology of anaplastic large cell Ki-1 lymphoma, an activated lymphocyte phenotype: a case report. Acta Cytol. 1996; 40(6): 1283-1288.
43. Moubayed P, Kaiserling E, Stein H. T-cell lymphomas of the stomach: morphological and immunological studies characterizing two cases of T-cell lymphoma. Virchows Arch A Pathol Anat Histopathol. 1987; 411 (6): 523-529.
44. Chong AL, Ngan BY, Weitzman S, Abla O. Anaplastic large cell lymphoma of the ovary in a pediatric patient. J Pediatr Hematol Oncol. 2009; 31 (9): 702-704.
45. Chen SC, Shih CM, Su JL, et al. Anaplastic large-cell lymphoma presenting as an endobronchial polypoid tumor. J Clin Oncol. 2008; 26(29): 4845-4847.
46. Recavarren RA, Yang J. Cytomorphologic features of primary anaplastic large cell lymphoma of the psoas muscle: a case report and literature review. Diagn Cytopathol. 2010; 38(3): 208-212.
47. Sanka RK, Eagle RC Jr, Wojno TH, Neufeld KR, Grossniklaus HE. Spectrum of CD30+ lymphoid proliferations in the eyelid lymphomatoid papulosis, cutaneous anaplastic large cell lymphoma, and anaplastic large cell lymphoma. Ophthalmology. 2010; 117(2): 343-351.
48. Chan AC, Chan JK, Yan KW, Kwong YL. Anaplastic large cell lymphoma presenting as a pleural effusion and mimicking primary effusion lymphoma: a report of 2 cases. Acta Cytol. 2003; 47(5): 809-816.
49. Lagmay J, Termuhlen A, Fung B, Ranalli M. Primary testicular presentation of ALK-1 -negative anaplastic large cell lymphoma in a pediatric patient. J Pediatr Hematol Oncol. 2009; 31(5): 330-332.
50. Agarwal M, Shenjere P, Blewitt RW, et al. CD30-positive T-cell lymphoproliferative disorder of the oral mucosa-an indolent lesion: report of 4 cases. Int J Surg Pathol. 2008; 16(3): 286-290.
51. Daneshbod Y, Oryan A, Khojasteh HN, Rasekhi A, Ahmadi N, Mohammadianpanah M. Primary ALK-positive anaplastic large cell lymphoma of the breast: a case report and review of the literature. J Pediatr Hematol Oncol. 2010; 32(2): e75-e78.
52. Miranda RN, Lin L, Talwalkar SS, Manning JT, Medeiros LJ. Anaplastic large cell lymphoma involving the breast: a clinicopathologic study of 6 cases and review of the literature. Arch Pathol Lab Med. 2009; 133(9): 1383-1390.
53. Roden AC, Macon WR, Keeney GL, Myers JL, Feldman AL, Dogan A. Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder. Mod Pathol. 2008; 21(4): 455-463.
54. de Jong D, Vasmel WL, de Boer JP, et al. Anaplastic large-cell lymphoma in women with breast implants. JAMA. 2008; 300(17): 2030-2035.
55. Krishnan C, Moline S, Anders K, Warnke RA. Intravascular ALK-positive anaplastic large-cell lymphoma mimicking inflammatory breast carcinoma. J Clin Oncol. 2009; 27(15): 2563-2565.
56. Mussolin L, Pillon M, d'Amore ES, et al. Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma. Leukemia. 2005; 19(9): 1643-1647.
57. Damm-Welk C, Busch K, Burkhardt B, et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic largecell lymphoma. Blood. 2007; 110(2): 670-677.
58. Lu Y, Zhao X, Wang E, Chen W, Huang Q. ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase." Leuk Res. 2010; 34(4): 475-482.
59. Nguyen JT, Condron MR, Nguyen ND, De J, Medeiros LJ, Padula A. Anaplastic large cell lymphoma in leukemic phase: extraordinarily high white blood cell count. Pathol Int. 2009; 59(5): 345-353.
60. Onciu M, Behm FG, Raimondi SC, et al. ALK-positive anaplastic large cell lymphoma with leukemic peripheral blood involvement is a clinicopathologic entity with an unfavorable prognosis: report of three cases and review of the literature. Am J Clin Pathol. 2003; 120(4): 617-625.
61. Ganesan P, Bakhshi S. Anaplastic large cell lymphoma: association with peripheral blood neutrophilia at presentation. Pediatr Blood Cancer. 2009; 52(2): 306-307.
62. Nishihira H, Tanaka Y, Kigasawa H, Sasaki Y, Fujimoto J. Ki-1 lymphoma producing G-CSF. Br J Haematol. 1992; 80(4): 556-557.
63. Sevilla DW, Choi JK, Gong JZ. Mediastinal adenopathy, lung infiltrates, and hemophagocytosis: unusual manifestation of pediatric anaplastic large cell lymphoma: report of two cases. Am J Clin Pathol. 2007; 127(3): 458-464.
64. Balachandran I, Walker JW Jr, Broman J. Fine needle aspiration cytology of ALK1(-), CD30+ anaplastic large cell lymphoma post renal transplantation: a case report and literature review. Diagn Cytopathol. 2010; 38(3): 213-216.
65. Azhir A, Reisi N, Taheri D, Adibi A. Post transplant anaplastic large T-cell lymphoma. Saudi J Kidney Dis Transpl. 2009; 20(4): 646-651.
66. Ravat FE, Spittle MF, Russell-Jones R. Primary cutaneous T-cell lymphoma occurring after organ transplantation. J Am Acad Dermatol. 2006; 54(4): 668-675.
67. Youd E, Boyde AM, Altanoos RL, Dojcinov SD. Small cell variant of anaplastic large cell lymphoma: a 10-year review of the All Wales Lymphoma Panel database. Histopathology. 2009; 55(3): 355-358.
68. Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood. 2000; 96(9): 2993-3000.
69. Jacobsen E. Anaplastic large-cell lymphoma, T-/null-cell type. Oncologist. 2006; 11(7): 831-840.
70. Hochberg J, Waxman IM, Kelly KM, Morris E, Cairo MS. Adolescent nonHodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol. 2009; 144(1): 24-40.
71. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26(25): 4124-4130.
72. Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol. 2004; 22(9): 1682-1688.
73. Rassidakis GZ, Goy A, Medeiros LJ, et al. Prognostic significance of MUC1 expression in systemic anaplastic large cell lymphoma. Clin Cancer Res. 2003; 9 (6): 2213-2220.
74. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Meijer CJ. ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects-a review. J Pathol. 2003; 200 (1): 4-15.
75. Chan JK, Buchanan R, Fletcher CD. Sarcomatoid variant of anaplastic large-cell Ki-1 lymphoma. Am J Surg Pathol. 1990; 14(10): 983-988.
76. Chott A, Kaserer K, Augustin I, et al. Ki-1 -positive large cell lymphoma: a clinicopathologic study of 41 cases. Am J Surg Pathol. 1990; 14(5): 439-448.
77. Bellas C, Molina A, Montalban C, Mampaso F. Signet-ring cell lymphoma of T-cell type with CD30 expression. Histopathology. 1993; 22(2): 188-189.
78. Cheuk W, Hill RW, Bacchi C, Dias MA, Chan JK. Hypocellular anaplastic large cell lymphoma mimicking inflammatory lesions of lymph nodes. Ami Surg Pathol. 2000; 24(11): 1537-1543.
79. Agnarsson BA, Kadin ME. Ki-1 positive large cell lymphoma: a morphologic and immunologic study of 19 cases. Ami Surg Pathol. 1988; 12(4): 264-274.
80. Vassallo J, Lamant L, Brugieres L, et al. ALK-positive anaplastic large cell lymphoma mimicking nodular sclerosis Hodgkin's lymphoma: report of 10 cases. Am J Surg Pathol. 2006; 30(2): 223-229.
81. Pileri SA, Pulford K, Mori S, et al. Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type. Am J Pathol. 1997; 150(4): 1207-1211.
82. Klapper W, Bohm M, Siebert R, Lennert K. Morphological variability of lymphohistiocytic variant of anaplastic large cell lymphoma (former lymphohistiocytic lymphoma according to the Kiel classification). Virchows Arch. 2008; 452 (6): 599-605.
83. Hodges KB, Collins RD, Greer JP, Kadin ME, Kinney MC. Transformation of the small cell variant Ki-1+ lymphoma to anaplastic large cell lymphoma: pathologic and clinical features. Am J Surg Pathol. 1999; 23(1): 49-58.
84. Wong KF, Chan JK, Ng CS, Chu YC, Lam PW, Yuen HL. Anaplastic large cell Ki-1 lymphoma involving bone marrow: marrow findings and association with reactive hemophagocytosis. Am J Hematol. 1991; 37(2): 112-119.
85. Fraga M, Brousset P, Schlaifer D, et al. Bone marrow involvement in anaplastic large cell lymphoma: immunohistochemical detection of minimal disease and its prognostic significance. Am) Clin Pathol. 1995; 103 (1): 82-89.
86. Tamaru J, Tokuhira M, Nittsu N, et al. Hodgkin-like anaplastic large cell lymphoma (previously designated in the REAL classification) has same immunophenotypic features to classical Hodgkin lymphoma. Leuk Lymphoma. 2007; 48(6): 1127-1138.
87. Daus H, Trumper L, Roth J, et al. Hodgkin and Reed-Sternberg cells do not carry T-cell receptor gamma gene rearrangements: evidence from single-cell polymerase chain reaction examination. Blood. 1995; 85(6): 1590-1595.
88. Muschen M, Rajewsky K, Brauninger A, et al. Rare occurrence of classical Hodgkin's disease as a T-cell lymphoma. J Exp Med. 2000; 191 (2): 387-394.
89. Seitz V, Hummel M, Marafioti T, Anagnostopoulos I, Assaf C, Stein H. Detection of clonal T-cell receptor gamma-chain gene rearrangements in ReedSternberg cells of classic Hodgkin disease. Blood. 2000; 95(10): 3020-3024.
90. Aguilera NS, Chen J, Bijwaard KE, et al. Gene rearrangement and comparative genomic hybridization studies of classic Hodgkin lymphoma expressing T-cell antigens. Arch Pathol Lab Med. 2006; 130 (12): 1772-1779.
91. Kadin ME, Muramoto L, Said J. Expression of T-cell antigens on ReedSternberg cells in a subset of patients with nodular sclerosing and mixed cellularity Hodgkin's disease. Am J Pathol. 1988; 130(2): 345-353.
92. Tzankov A, Bourgau C, Kaiser A, et al. Rare expression of T-cell markers in classical Hodgkin's lymphoma. Mod Pathol. 2005; 18 (12):1542-1549.
93. Felgar RE, Macon WR, Kinney MC, Roberts S, Pasha T, Salhany KE. TIA-1 expression in lymphoid neoplasms: identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol. 1997; 150 (6): 1893-1900.
94. Bakshi NA, Finn WG, Schnitzer B, Valdez R, Ross CW. Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma. Arch Pathol Lab Med. 2007; 131 (5): 742-747.
95. Nascimento AF, Pinkus JL, Pinkus GS. Clusterin, a marker for anaplastic large cell lymphoma immunohistochemical profile in hematopoietic and nonhematopoietic malignant neoplasms. Am J Clin Pathol. 2004; 121 (5): 709-717.
96. Dogan A, Gaulard P, Jaffe ES, Ralfkiaer E, Muller-Hermelink HK. Angioimmunoblastic T-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008: 309-311.
97. World Health Organization Classification of Tumours; vol 3
98. Rekhi B, Sridhar E, Viswanathan S, Shet TM, Jambhekar NA. ALK+ anaplastic large cell lymphoma with cohesive, perivascular arrangements on cytology, mimicking a soft tissue sarcoma: a report of 2 cases. Acta Cytol. 2010; 54 (1): 75-78.
99. Felgar RE, Salhany KE, Macon WR, Pietra GG, Kinney MC. The expression of TIA-1+ cytolytic-type granules and other cytolytic lymphocyte-associated markers in CD30+ anaplastic large cell lymphomas (ALCL): correlation with morphology, immunophenotype, ultrastructure, and clinical features. Hum Pathol. 1999; 30(2): 228-236.
100. Saffer H, Wahed A, Rassidakis GZ, Medeiros LJ. Clusterin expression in malignant lymphomas: a survey of 266 cases. Mod Pathol. 2002; 15(11): 1221-1226.
101. Lae ME, Ahmed I, Macon WR. Clusterin is widely expressed in systemic anaplastic large cell lymphoma but fails to differentiate primary from secondary cutaneous anaplastic large cell lymphoma. Am J Clin Pathol. 2002; 118(5): 773-779.
102. Wellmann A, Thieblemont C, Pittaluga S, et al. Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood. 2000; 96(2): 398-404.
103. Kitamura N, Katagiri YU, ltagaki M, et al. The expression of granulysin in systemic anaplastic large cell lymphoma in childhood. Leuk Res. 2009; 33(7): 908-912.
104. Delsol G, Al Saati T, Gatter KC, et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas: diagnostic value in so-called malignant histiocytosis. Am J Pathol. 1988; 130(1): 59-70.
105. Bonzheim I, Geissinger E, Roth S, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood. 2004; 104(10): 3358-3360.
106. Macon WR, Casey TT, Kinney MC, Collins RD, Cousar JB. Leu-22 (L60): a more sensitive marker than UCHL1 for peripheral T-cell lymphomas, particularly large-cell types. Am J Clin Pathol. 1991; 95(5): 696-701.
107. Foss HD, Anagnostopoulos I, Araujo I, et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood. 1996; 88 (10): 4005-4011.
108. Tan BT, Seo K, Warnke RA, Arber DA. The frequency of immunoglobulin heavy chain gene and T-cell receptor gamma-chain gene rearrangements and Epstein-Barr virus in ALK+ and ALK- anaplastic large cell lymphoma and other peripheral T-cell lymphomas. J Mol Diagn. 2008; 10(6): 502-512.
109. Kinney MC, Glick AD, Stein H, Collins RD. Comparison of anaplastic large cell Ki-1 lymphomas and microvillous lymphomas in their immunologic and ultrastructural features. Am J Surg Pathol. 1990; 14(11): 1047-1060.
110. Donner LR, Pugh WC, Harms D. Keratin-positive, epithelial membrane antigen-positive solitary pelvic tumor with ultrastructural features of large cell lymphoma. Ultrastruct Pathol. 1993; 17(3-4): 455-458.
111. Gustmann C, Altmannsberger M, Osborn M, Griesser H, Feller AC. Cytokeratin expression and vimentin content in large cell anaplastic lymphomas and other non-Hodgkin's lymphomas. Am J Pathol. 1991; 138(6): 1413-1422.
112. Gustafson S, Medeiros LJ, Kalhor N, Bueso-Ramos CE. Anaplastic large cell lymphoma: another entity in the differential diagnosis of small round blue cell tumors. Ann Diagn Pathol. 2009; 13(6): 413-427.
113. Sung CO, Ko YH, Park S, Kim K, Kim W. Immunoreactivity of CD99 in non-Hodgkin's lymphoma: unexpected frequent expression in ALK-positive anaplastic large cell lymphoma. J Korean Med Sci. 2005; 20(6): 952-956.
114. Buxton D, Bacchi CE, Gualco G, et al. Frequent expression of CD99 in anaplastic large cell lymphoma: a clinicopathologic and immunohistochemical study of 160 cases. Am J Clin Pathol. 2009; 131(4): 574-579.
115. Leong MY, English M, McMullan D, Ramani P. Aberrant expression of beta-HCG in anaplastic large cell lymphoma. Pediatr Dev Pathol. 2008; 11(3): 230-234.
116. Guaico G, Chioato L, Weiss LM, Harrington WJ Jr, Bacchi CE. Analysis of human T-cell lymphotropic virus in CD25+ anaplastic large cell lymphoma in children. Am J Clin Pathol. 2009; 132 (1): 28-33.
117. Muzzafar T, Wei EX, Lin P, Medeiros LJ, Jorgensen JL. Flow cytometric immunophenotyping of anaplastic large cell lymphoma. Arch Pathol Lab Med. 2009; 133 (1): 49-56.
118. Bovio IM, Allan RW. The expression of myeloid antigens CD13 and/or CD33 is a marker of ALK+ anaplastic large cell lymphomas. Am ) Clin Pathol. 2008; 130(4): 628-634.
119. Juco J, Holden JT, Mann KP, Kelley LG, Li S. Immunophenotypic analysis of anaplastic large cell lymphoma by flow cytometry. Am J Clin Pathol. 2003; 119(2): 205-212.
120. Kesler MV, Paranjape GS, Asplund SL, McKenna RW, Jamal S, Kraft SH. Anaplastic large cell lymphoma: a flow cytometric analysis of 29 cases. Am J Clin Pathol. 2007; 128(2): 314-322.
121. Simonitsch I, Panzer-Gruemayer ER, Ghali DW, et al. NPM/ALK gene fusion transcripts identify a distinct subgroup of null type Ki-1 positive anaplastic large cell lymphomas. Br J Haematol. 1996; 92(4): 866-871.
122. Dunphy CH, Gardner LJ, Manes JL, Bee CS, Taysi K. CD30+ anaplastic large-cell lymphoma with aberrant expression of CDI3: case report and review of the literature. ) Clin Lab Anal. 2000; 14(6): 299-304.
123. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Reseach and Tretment of Cancer. Boold.1997;90 (1):355-371
124. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997; 90(1): 354-371.
125. Guitart J, Querfeld C. Cutaneous CD30 lymphoproliferative disorders and similar conditions: a clinical and pathologic prospective on a complex issue. Semin Diagn Pathol. 2009; 26(3): 131-140.
126. Droc C, Cualing HD, Kadin ME. Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin. Cancer Control. 2007; 14(2): 124-132.
127. Sasaki K, Sugaya M, Fujita H, et al. A case of primary cutaneous anaplastic large cell lymphoma with variant anaplastic lymphoma kinase translocation. Br J Dermatol. 2004; 150(6): 1202-1207.
128. DeCoteau JF, Butmarc JR, Kinney MC, Kadin ME. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood. 1996;87(8):3437-3441.
129. Kadin ME, Pinkus JL, Pinkus GS, et al. Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative. Am J Surg Pathol. 2008;32(9):1421-1426.
130. Su LD, Schnitzer B, Ross CW, et al. The t(2;5)-associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders. J Cutan Pathol. 1997;24 10:597-603.
131. Tomaszewski MM, Moad JC, Lupton GP. Primary cutaneous KI-(CD30) positive anaplastic large cell lymphoma in childhood. J Am Acad Dermatol. 1999;40(5, pt 2):857-861.
132. Fink-Puches R, Chott A, Ardigo M, et al. The spectrum of cutaneous lymphomas in patients less than 20 years of age. Pediatr Dermatol. 2004;21(5): 525-533.
133. Kumar S, Pittaluga S, Raffeld M, Guerrera M, Seibel NL, Jaffe ES. Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature. Pediatr Dev Pathol. 2005;801:52-60.
134. Hung TY, Lin YC, Sun HL, Liu MC. Primary cutaneous anaplastic large cell lymphoma in a young child. Eur J Pediatr. 2008;167(1):111-113.
135. Hazneci E, Aydin NE, Dogan G, Turhan IO. Primary cutaneous anaplastic large cell lymphoma in a young girl. J Eur Acad Dermatol Venereol. 2001;15(4):366-367.
136. Motley RJ, Jasani B, Ford AM, Poynton CH, Calonje-Daly JE, Holt PJ. Regressing atypical histiocytosis, a regressing cutaneous phase of Ki-1-positive anaplastic large cell lymphoma: immunocytochemical, nucleic acid, and cytogenetic studies of a new case in view of current opinion. Cancer. 1992; 70(2):476-483.
137. Chen RF, Chen CT, Liao HT, Chen CH, Chen YR. Primary cutaneous anaplastic large cell lymphoma of the face presenting as posttraumatic maxillary sinusitis. J Craniofac Surg. 2008;19(6):1597-1599.
138. Fletcher CL, Orchard GE, Hubbard V, Whittaker SJ, Edelson RL, RussellJones R. CD30(+) cutaneous lymphoma in association with atopic eczema. Arch Dermatol. 2004;140(4):449-454.
139. Kadin ME. Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders. Oncology (Williston Park). 2009;23(13):1158-1164.
140. Benner MF, Willemze R. Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma. Arch Dermatol. 2009;145(12):1399-1404.
141. Woo DK, Jones CR, Vanoli-Storz MN, et al. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol. 2009; 145(6):667-674.
142. Beljaards RC, Kaudewitz P, Berti E, et al. Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis: a European Multicenter Study of 47 patients. Cancer. 1993: 71 (6):2097-2104.
143. Paulli M, Berti E, Rosso R, et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin-clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol. 1995; 13(6):1343-1354.
144. Ando K, Tamada Y, Shimizu K, et al. ALK-positive primary systemic anaplastic large cell lymphoma with extensive cutaneous manifestation. Acta Derm Venereol. 2010;90(2):198-200.
145. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95(12):3653-3661.
146. Yamane N, Kato N, Nishimura M, lto M, Yanagi T, Osawa R. Primary cutaneous CD30+ anaplastic large-cell lymphoma with generalized skin involvement and involvement of one peripheral lymph node, successfully treated with low-dose oral etoposide. Clin Exp Dermatol. 2009;34(5):e56-e59.
147. Rannan-Eliya YF, Pulford K, Johnson R, et al. Isolated cutaneous anaplastic large cell lymphoma progressing to severe systemic disease with myocardial involvement and central nervous system infiltration. Pediatr Blood Cancer. 2008;50(4):879-881.
148. Alobeid B, Pan LX, Milligan L, Budel L, Frizzera G. Eosinophil-rich CD30+ lymphoproliferative disorder of the oral mucosa: a form of "traumatic eosinophilic granuloma." Am J Clin Pathol. 2004;121(1):43-50.
149. Massone C, El-Shabrawi-Caelen L, Kerl H, Cerroni L. The morphologic spectrum of primary cutaneous anaplastic large T-cell lymphoma: a histopathologic study on 66 biopsy specimens from 47 patients with report of rare variants. J Cutan Pathol. 2008;35(1):46-53.
150. Kamiya T, Saga K, Yanagisawa K, et al. Small cell variant of CD30+ primary cutaneous T-cell lymphoma with epidermotropism that completely regressed after incisional skin biopsy. Br J Dermatol. 2006;155(2):484-487.
151. Mann KP, Hall B, Kamino H, Borowitz MJ, Ratech H. Neutrophil-rich, Ki1-positive anaplastic large-cell malignant lymphoma. Am J Surg Pathol. 1995; 19(41:407-416.
152. Kong YY, Dai B, Kong JC, Lu HF, Shi DR. Neutrophil/eosinophil-rich type of primary cutaneous anaplastic large cell lymphoma: a clinicopathological, immunophenotypic and molecular study of nine cases. Histopathology. 2009; 55(2):189-196.
153. Bittencourt AL, Rothers S, Boente P, Santos R. Primary cutaneous eosinophil-rich anaplastic large cell lymphoma: report of an unusual case and literature review. ; Cutan Med Surg. 2008;12(2):88-92.
154. Zayour M, Gilmore E, Heald P, Rose M, Poligone B, Lazova R. A distinct entity in the spectrum of the CD30+ cutaneous lymphoproliferative diseases: oligolesional nodules with pseudoepitheliomatous hyperplasia followed by spontaneous resolution. Am J Dermatopathol. 2009;31(1):37-43.
155. Courville P, Wechsler J, Thomine E, et al. Pseudoepitheliomatous hyperplasia in cutaneous T-cell lymphoma: a clinical, histopathological and immunohistochemical study with particular interest in epithelial growth factor expression-The French Study Group on Cutaneous Lymphoma. Br J Dermatol. 1999;140(3):421-426.
156. Magro CM, Dyrsen ME. Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates. J Cutan Pathol. 2008;35(11):1040-1049.
157. Vergier B, Beylot-Barry M, Pulford K, et al. Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases. Am J Surg Pathol. 1998,22(10): 1192-1202.
158. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol. 2000;53(6):445-450.
159. Goteri G, Simonetti O, Rupoli S, et al. Differences in survivin location
160. Natkunam Y, Warnke RA, Haghighi B, et al. Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases. J Cutan Pathol. 2000;27(8):392-399.
161. Benner MF, Jansen PM, Meijer CJ, Willemze R. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol. 2009; 161(1):121-127.
162. Wasco MJ, Fullen D, Su L, Ma L. The expression of MUM1 in cutaneous T-cell lymphoproliferative disorders. Hum Pathol. 2008;39(4):557-563.
163. Assaf C, Hirsch B, Wagner F, et al. Differential expression of TRAF1 aids in the distinction of cutaneous CD30-positive lymphoproliferations. J Invest Dermatol. 2007;127(8):1898-1904.
164. Kempf W, Levi E, Kamarashev J, et al. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders. J Cutan Pathol. 2002;29(5):295-300.
165. Shiohara J, Koga H, Uhara H, Takata M, Saida T, Uehara T. Herpes zoster histopathologically mimicking CD30-positive anaplastic large cell lymphoma. J. Eur Acad Dermatol Venereol. 2009;23(5):618-619.
166. Leinweber B, Kerl H, Cerroni L. Histopathologic features of cutaneous herpes virus infections (herpes simplex, herpes varicella/zoster): a broad spectrum of presentations with common pseudolymphomatous aspects. Am J Surg Pathol. 2006;30(1):50-58.
167. Werner B, Massone C, Kerl H, Cerroni L. Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin. J Cutan Pathol. 2008;35(12): 1100-1107.
168. Salhany KE, Cousar JB, Greer JP, Casey TT, Fields JP, Collins RD. Transformation of cutaneous T cell lymphoma to large cell lymphoma: a clinicopathologic and immunologic study. Am J Pathol. 1988;132(2):265-277.
169. Vergier B, de Muret A, Beylot-Barry M, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. Blood. 2000; 95(7):2212-2218.
170. El Shabrawi-Caelen L, Kerl H, Cerroni L. Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C. Arch Dermatol. 2004;140(4):441-447.
171. Kinney MC, Kadin ME. The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation. Am J Clin Pathol. 1999;111(1 suppl 1):S56-S67.
172. Nijsten T, Curiel-Lewandrowski C, Kadin ME. Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. Arch Dermatol. 2004; 140(3):306-312.
173. Yamaguchi T, Ohshima K, Karube K, et al. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders. Br J Dermatol. 2006;154(5):904-909.
174. Webb TR, Slavish J, George RE, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Fxpert Rev Anticancer Ther. 2009;9(3):331-356.
175. Tartari CJ, Gunby RH, Coluccia AM, et al. Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. J Biol Chem. 2008;283(7):3743-3750.
176. Morris SW, Naeve C, Mathew P, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene. 1997;14(18):2175-2188.
177. Souttou B, Carvalho NB, Raulais D, Vigny M. Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J Biol Chem. 2001; 276(21):9526-9531.
178. Piccinini G, Bacchiocchi R, Serresi M, et al. A ligand-inducible epidermal growth factor receptor/anaplastic lymphoma kinase chimera promotes mitogenesis and transforming properties in 3T3 cells. J Biol Chem. 2002;277(25): 22231-22239.
179. Perez-Pinera P, Zhang W, Chang Y, Vega JA, Deuel TF. Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation. J Biol Chem. 2007;282(39):28683-28690.
180. Delsol G, Campo E, Gascoyne RD. ALK-positive large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL et al, eds. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:254-255. World Health Organization Classification of Tumours; vol 3.
181. Laurent C, Do C, Gascoyne RD, et al. Anaplastic lymphoma kinasepositive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol. 2009;27(25):4211-4216.
182. Perez-Pinera P, Chang Y, Astudillo A, Mortimer J, Deuel TF. Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer. Biochem Biophys Res Commun. 2007;358(2):399-403.
183. Dirks WG, Fahnrich S, Lis Y, Becker E, MacLeod RA, Drexler HG. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int J Cancer. 2002;100(1):49-56.
184. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448(7153): 561-566.
185. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11-23.
186. Passoni L, Longo L, Collini P, et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res. 2009,69(18):7338-7346.
187. Chan JK, Lamant L, Algar E, et al. ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. Blood. 2008;112(7): 2965-2968.
188. Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 1999;59(12):2776-2780.
189. Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol. 2001 ;14(6):569-576.
190. Cook JR, Dehner LP, Collins MH, et al. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol. 2001;25(11):1364-1371.
191. Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? ; Clin Pathol. 2008;61 (4):428-437.
192. Jiang YH, Cheng B, Ge MH, Cheng Y, Zhang G. Comparison of the clinical and immunohistochemical features, including anaplastic lymphoma kinase (ALK) and p53, in inflammatory myofibroblastic tumours. J Int Med Res. 2009;37(3):867-877.
193. Mathas S, Kreher S, Meaburn KJ, et al. Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma. Proc Natl Acad Sci USA. 2009;106(14):5831-5836.
194. Cotta CV, Leventaki V, Atsaves V, et al. The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas. Cancer. 2008;112(3):552-561.
195. Morris SW, Xue L, Ma Z, Kinney MC. Alk+ CD30+ lymphomas: a distinct molecular genetic subtype of non-Hodgkin's lymphoma. Br J Haematol. 2001; 113(2):275-295.
196. Liu QR, Chan PK. Formation of nucleophosmin/B23 oligomers requires both the amino- and the carboxyl-terminal domains of the protein. Eur J Biochem. 1991 ;200(3):715-721.
197. Adachi Y, Copeland TD, Hatanaka M, Oroszlan S. Nucleolar targeting signal of Rex protein of human T-cell leukemia virus type I specifically binds to nucleolar shuttle protein B-23. J Biol Chem. 1993;268(19):13930-13934.
198. Niitsu N, Kohri M, Hayama M, Tamaru J, Miura I. ALK-positive anaplastic large cell lymphoma with dic(2;4)(p23;q33). Leuk Res. 2009;33(6):e23-e25.
199. Bridge JA, Kanamori M, Ma Z, et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol. 2001;159(2):411-415.
200. Cools J, Wlodarska I, Somers R, et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer. 2002;34(4):354-362.
201. Panagopoulos I, Nilsson T, Domanski HA, et al. Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int J Cancer. 2006; 118(5):1181-1186.
202. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190-1203.
203. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3(1): 13-17.
204. Perner S, Wagner PL, Demichelis F, et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia. 2008;10(3):298-302.
205. Shinmura K, Kageyama S, Tao H, et al. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATtC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer. 2008;61(2):163-169.
206. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009; 15(9):3143-3149.
207. Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol. 2009;40(8):1152-1158.
208. Sozzi G, Martelli MP, Conte D, et al. The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues. Haematologica. 2009;94(9):1307-1311.
209. Fornari A, Piva R, Chiarle R, Novero D, lnghirami G. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? Hematol Oncol. 2009; 27(4):161-170.
210. Wasik MA, Zhang Q, Marzec M, Kasprzycka M, Wang HY, Liu X. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches. Semin Oncol. 2009; 36(2 suppl 1):S27-S35.
211. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J. 2009;420(3):345-361.
212. Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood. 2007;110(7):2259-2267.
213. Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol. 2004;199(3):330-358.
214. Bai RY, Dieter P, Peschel C, Morris SW, Duyster J. Nucleophosminanaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol. 1998;18(12):6951-6961.
215. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic largecell lymphoma activates the phosphatidyl inositol 3-kinase/Akt antiapoptotic signaling pathway. Blood. 2000;96(13):4319-4327.
216. Bischof D, Pulford K, Mason DY, Morris SW. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol. 1997; 17(4):23122325.
217. Ambrogio C, Voena C, Manazza AD, et al. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood. 2005;106(12): 3907-3916.
218. Cussac D, Greenland C, Roche S, et al. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood. 2004;103(4):1464-1471.
219. Chiarle R, Simmons WJ, Cai H, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005; 11(6):623-629.
220. Zamo A, Chiarle R, Piva R, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene. 2002;21(7):1038-1047.
221. Zhang Q, Raghunath PN, Xue L, et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol. 2002;168(1):466-474.
222. Marzec M, Kasprzycka M, Ptasznik A, et al. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab Invest. 2005;85(12): 1544-1554.
223. Piva R, Pellegrino E, Mattioli M, et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest. 2006;116(12):3171-3182.
224. Coluccia AM, Perego S, Cleris L, et al. Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo. Blood. 2004;103(7):2787-2794.
225. Jundt F, Raetzel N, Muller C, et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein (beta) and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood. 2005;106(5):1801-1807.
226. Amin HM, McDonnell TJ, Ma Y, et al. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene. 2004;23(32):5426-5434.
227. Inghirami G, Macri L, Cesarman E, Chadburn A, Zhong J, Knowles DM. Molecular characterization of CD30+ anaplastic large-cell lymphoma: high frequency of c-myc proto-oncogene activation. Blood. 1994;83(12):3581-3590.
228. Raetz EA, Perkins SL, Carlson MA, Schooler KP, Carroll WL, Virshup DM. The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas. Am J Pathol. 2002; 161(3):875-883.
229. Wellmann A, Doseeva V, Butscher W, et al. The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts. FASEB J. 1997;11(12):965-972.
230. Quintanilla-Martinez L, Pittaluga S, Miething C, et al. NPM-ALKdependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma. Blood. 2006; 108(6):2029-2036.
231. Anastasov N, Bonzheim I, Rudelius M, et al. C/EBPbeta expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway. Haematologica. 2010;95(5): 760-767.
232. Tsuchiya T, Ohshima K, Karube K, et al. Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood. 2004; 103(1):236-241.
233. Groner B, Lucks P, Borghouts C. The function of STAT3 in tumor cells and their microenvironment. Semin Cell Dev Biol. 2008;19(4):341-350.
234. Bard JD, Gelebart P, Anand M, Amin HM, Lai R. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. Leukemia. 2008;22(8):1595-1603.
235. Nieborowska-Skorska M, Slupianek A, Xue L, et al. Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res. 2001;611(7):6517-6523.
236. Zhang Q, Wang HY, Liu X, Wasik MA. STAT5A is epigenetically silenced by the tyrosine kinase NPMI-ALK and aas as a tumor suppressor by reciprocally inhibiting NPMI-ALK expression. Nat Med. 2007;13(11):1341-1348.
237. Khoury JD, Rassidakis GZ, Medeiros LJ, Amin HM, Lai R. Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma. Blood. 2004; 104(5): 1580-1581.
238. Han Y, Amin HM, Frantz C, et al. Restoration of SHPI expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. Leukemia. 2006; 20(9): 1602-1609.
239. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489-501.
240. Gu TL, Tothova Z, Scheijen B, Griffin JD, Gilliland DG, Sternberg DW. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood. 2004;103(12): 4622-4629.
241. Rassidakis GZ, Feretzaki M, Atwell C, et al. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood. 2005;105(2):827-829.
242. Fernandez-Vidal A, Mazars A, Gautier EF, Prevost G, Payrastre B, Manenti S. Upregulation of the CDC25A phosphatase down-stream of the NPM/ ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation. Cell Cycle. 2009;8(9):1373-1379.
243. Slupianek A, Skorski T. NPM/ALK downregulates p27Kip1 in a PI-3Kdependent manner. Exp Hematol. 2004;32(12):1265-1271.
244. Vega F, Medeiros LJ, Leventaki V, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 2006; 66(13):6589-6597.
245. Marzec M, Kasprzycka M, Liu X, et al. Oncogenic tyrosine kinase NPM/ ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene. 2007;26(38):5606-5614.
246. Slupianek A, Nieborowska-Skorska M, Hoser G, et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 2001;61(5):2194-2199.
247. Singh RR, Cho-Vega JH, Davuluri Y, et al. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. Cancer Res. 2009;69(6):2550-2558.
248. Fujimoto J, Shiota M, Iwahara T, et al. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci USA. 1996; 93(9):4181-4186.
249. Voena C, Conte C, Ambrogio C, et al. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res. 2007;67(9):4278-4286.
250. Chikamori M, Fujimoto J, Tokai-Nishizumi N, Yamamoto T. Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation. Oncogene. 2007;26(20):2950-2954.
251. Leventaki V, Drakos E, Medeiros LJ, et al. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma. Blood. 2007;110(5): 1621-1630.
252. Drakos E, Leventaki V, Schiene EJ, et al. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders. Am J Surg Pathol. 2007; 31(3):447-453.
253. Rassidakis GZ, Thomaides A, Atwell C, et al. JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol. 2005;18(10):1365-1370.
254. Mathas S, Hinz M, Anagnostopoulos I, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J. 2002;21(15):4104-4113.
255. Watanabe M, Sasaki M, Itoh K, et al. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and Reed-Sternberg cells of Hodgkin lymphoma. Cancer Res. 2005;65(17):7628-7634.
256. Franchina M, Woo AJ, Dods J, et al. The CD30 gene promoter microsatellite binds transcription factor Yin Yang 1 (YY1) and shows genetic instability in anaplastic large cell lymphoma. J Pathol. 2008;214(1):65-74. 253.
257. Turner SD, Tooze R, Maclennan K, Alexander DR. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene. 2003;22(49):7750-7761.
258. Cui YX, Kerby A, McDuff FK, Ye H, Turner SD. NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner. Blood. 2009;113(21):5217-5227.
259. Persad S, Troussard AA, McPhee TR, Mulholland DJ, Dedhar S. Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T-cell/ lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol. 2001 ; 153(6):1161-1174.
260. Dorfman DM, Greisman HA, Shahsafaei A. Loss of expression of the WNT/beta-catenin-signaling pathway transcription factors lymphoid enhancer factor-1 (LEF-1) and T cell factor-1 (TCF-1) in a subset of peripheral T-cell lymphomas. Am J Pathol. 2003;162(5):1539-1544.
261. Beilei B, Pacchiarotti A, Perez M, Faraggiana T. Frequent beta-catenin overexpression without exon 3 mutation in cutaneous lymphomas. Mod Pathol. 2004;17(10):1275-1281.
262. Uner AH, Saglam A, Han U, Hayran M, Sungur A, Ruacan S. PTEN and p27 expression in mature T-cell and NK-cell neoplasms. Leuk Lymphoma. 2005; 46(10):1463-1470.
263. Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld M. PTEN gene alterations in lymphoid neoplasms. Blood. 1998;92(9):3410-3415.
264. Radtke F, Wilson A, Mancini SJ, MacDonald HR. Notch regulation of lymphocyte development and function. Nat Immunol. 2004;5(3):247-253.
265. Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notchl signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002;99(9):3398-3403.
266. Joshi I, Minter LM, Telfer J, et al. Notch signaling mediates G1/S cellcycle progression in T-cells via cyclin D3 and its dependent kinases. Blood. 2009; 113(8): 1689-1698.
267. Spaulding C, Reschly EJ, Zagort DE, et al. Notchl co-opts lymphoid enhancer factor 1 for survival of murine T-cell lymphomas. Blood. 2007;110(7): 2650-2658.
268. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood. 2007;110(1):278-286.
269. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-Myc is an important direct target of Notchl in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 2006;20(15):2096-2109.
270. Nagasawa T, Zhang Q, Raghunath PN, et al. Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing. Leuk Res. 2006;30(3):303-312.
271. Honorat JF, Ragab A, Lamant L, Delsol G, Ragab-Thomas J. SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling. Blood. 2006;107(10):4130-4138.
272. Zhang Q, Wang HY, Marzec M, Raghunath PN, Nagasawa T, Wasik MA. STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci U S A. 2005;102(19):6948-6953.
273. Zhang Q, Wang HY, Bhutani G, et al. Lack of TNFalpha expression protects anaplastic lymphoma kinase-positive T-cell lymphoma (ALK+ TCL) cells from apoptosis. Proc Natl Acad Sci USA. 2009;106(37):15843-15848.
274. Akimzhanov A, Krenacs L, Schlegel T, et al. Epigenetic changes and suppression of the nuclear factor of activated T cell 1 (NFATC1) promoter in human lymphomas with defects in immunoreceptor signaling. Am J Pathol. 2008; 172(1 ):215-224.
275. Turner SD, Yeung D, Hadfield K, Cook SJ, Alexander DR. The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms. Cell Signal. 2007;19(4):740-747.
276. Lim MS, Carlson ML, Crockett DK, et al. The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways. Blood. 2009; 114(8):585-1595.
277. Ventura RA, Martin-Subero JI, Knippschild U, et al. Centrosome abnormalities in ALK-positive anaplastic large-cell lymphoma. Leukemia. 2004; 18(11):910-1911.
278. Horie R, Watanabe M, Ishida T, et al. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma. Cancer Cell. 2004;5(4):353-364.
279. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998; 279(5350):509-514.
280. Boccalatte FE, Voena C, Riganti C, et al. The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. Blood. 2009;113(12):2776-2790.
281. Armstrong F, Duplantier MM, Trempat P, et al. Differential effects of XALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene. 2004;23(36):6071-6082.
282. Mosse YP, Wood A, Maris JM. Inhibition of ALK signaling for cancer therapy. Clin Cancer Res. 2009;15(18):5609-5614.
283. Crockett DK, Lin Z, Elenitoba-Johnson KS, Lim MS. Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene. 2004; 23(15):2617-2629.
284. Lim MS, Elenitoba-Johnson KS. Mass spectrometry-based proteomic studies of human anaplastic large cell lymphoma. Mol Cell Proteomics. 2006; 5(10):787-1798.
285. Elenitoba-Johnson KS, Crockett DK, Schumacher JA, et al. Proteomic identification of oncogenic chromosomal translocation partners encoding chimeric anaplastic lymphoma kinase fusion proteins. Proc Natl Acad Sci U S A. 2006;103(19):7402-7407.
286. Sjostrom C, Seiler C, Crockett DK, Tripp SR, Elenitoba Johnson KS, Lim MS. Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma. Exp Hematol. 2007;35(8):1240-1248.
287. Wu F, Wang P, Young LC, Lai R, Li L. Proteome-wide identification of novel binding partners to the oncogenic fusion gene protein, NPM-ALK, using tandem affinity purification and mass spectrometry. Am J Pathol. 2009;174(2): 361-370.
288. Fawal M, Armstrong F, Oilier S, et al. A "liaison dangereuse" between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK. Blood. 2006; 108(8):2 780-2 788.
289. Galietta A, Gunby RH, Redaelli S, et al. NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma. Blood. 2007;110(7):2600-2609.
290. Cussac D, Pichereaux C, Colomba A, et al. Proteomic analysis of anaplastic lymphoma cell lines: identification of potential tumour markers. Proteomics. 2006;6(10):3210-3222.
291. Ouyang T, Bai RY, Bassermann F, et al. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA). J Biol Chem. 2003;278(32):30028-30036.
292. Bassermann F, von Klitzing C, Munch S, et al. NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry. Cell. 2005;122(1):45-57.
293. Bassermann F, von Klitzing C, Illert AL, et al. Multisite phosphorylation of nuclear interaction partner of ALK (NIPA) at G2/M involves cyclin B1/Cdk1. J Biol Chem. 2007;282(22):15965-15972.
294. Bonvini P, Dalla Rosa H, Vignes N, Rosolen A. Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein. Cancer Res. 2004;64(9): 3256-3264.
295. Bonvini P, Gastaldi T, Falini B, Rosolen A. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: downregulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+1 lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethox-ygeldanamycin. Cancer Res. 2002;62(5):1559-1566.
296. Shi P, Lai R, Lin Q, et al. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. Blood. 2009;114(2):360-370.
297. Colomba A, Courilleau D, Ramel D, et al. Activation of Raci and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas. Oncogene. 2008;27(19):2728-2736.
298. Ambrogio C, Voena C, Manazza AD, et al. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res. 2008;68(21):8899-8907.
299. Ambrogio C, Martinengo C, Voena C, et al. NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res. 2009;69(22):8611-8619.
300. Oyarzo MP, Medeiros LJ, Atwell C, et al. c-FLIP confers resistance to FASmediated apoptosis in anaplastic large-cell lymphoma. Blood. 2006; 107(6): 2544-2547.
301. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994;83(8):2045-2056.
302. Mir SS, Richter BW, Ducken CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000;96(13): 4307-4312.
303. Hubinger G, Muller E, Scheffrahn I, et al. CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. Oncogene. 2001;20(5):590-598.
304. Levi E, Pfeifer WM, Kadin ME. CD30-activation-mediated growth inhibition of anaplastic large-cell lymphoma cell lines: apoptosis or cell-cycle arrest? Blood. 2001;98(5):1630-1632.
305. Wright CW, Rumble JM, Duckett CS. CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. J Biol Chem. 2007;282(14):10252-10262.
306. Hirsch B, Hummel M, Bentink S, et al. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. Am J Pathol. 2008;172(2):510-520.
307. Marzec M, Zhang Q, Goradia A, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PDL1, B7-H1). Proc Natl Acad Sci U S A. 2008;105(52):20852-20857.
308. Kasprzycka M, Marzec M, Liu X, Zhang Q, Wasik MA. Nucleophosmin/ anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci USA. 2006;103(26): 9964-9969.
309. Rodig SJ, Ouyang J, Juszczynski P, et al. API-dependent galectin-1 expression delineates classical Hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. Clin Cancer Res. 2008;14(11):3338-3344.
310. Duplantier MM, Lamant L, Sabourdy F, de Reynies A, Delsol G, Espinos E. Serpin Al is overexpressed in ALK+ anaplastic large cell lymphoma and its expression correlates with extranodal dissemination. Leukemia. 2006;20(10): 1848-1854.
311. Thompson MA, Stumph J, Henrickson SE, et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol. 2005;36(5):494-504.
312. Ballester B, Ramuz O, Gisselbrecht C, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene. 2006;25(10):1560-1570.
313. Lamant L, de Reynies A, Duplantier MM, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood. 2007;109(5):2156-2164.
314. Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115(5):1026-1036.
315. Zettl A, Rudiger T, Konrad MA, et al. Genomic profiling of peripheral Tcell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol. 2004;164(5):1837-1848.
316. Nelson M, Horsman DE, Weisenburger DD, et al. Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. Br J Haematol. 2008;141(4):461-469.
317. Salaverria I, Bea S, Lopez-Guillermo A, et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol. 2008; 140(5):516-526.
318. Fadlelmola FM, Zhou M, de Leeuw RJ, et al. Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma cell lines. Mol Cancer. 2008;7:2.
319. Youssif C, Goldenbogen J, Hamoudi R, et al. Genomic profiling of pediatric ALK-positive anaplastic large cell lymphoma: a Children's Cancer and Leukaemia Group Study. Genes Chromosomes Cancer. 2009;48(11):1018-1026.
320. Schiemann WP, Pfeifer WM, Levi E, Kadin ME, Lodish HF. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. Blood. 1999;94(8):2854-2861.
321. Schiemann WP, Rotzer D, Pfeifer WM, et al. Transforming growth factorbeta (TGF-beta)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF-beta receptor. Cancer Detect Prev. 2004;28(1):57-64.
322. Knaus PI, Lindemann D, DeCoteau JF, et al. A dominant inhibitory mutant of the type Il transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol Cell Biol. 1996;16(7):3480-3489.
323. Kamstrup MR, Ralfkiaer E, Skovgaard GL, Gniadecki R. Potential involvement of Notchl signalling in the pathogenesis of primary cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol. 2008;158(4):747-753.
324. Kleinhans M, Tun-Kyi A, Gilliet M, et al. Functional expression of the
325. Yagi H, Tokura Y, Furukawa F, Takigawa M. Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-gamma. J Invest Dermatol. 1996;107(6):827-832.
326. Bijl JJ, van Oostveen JW, Walboomers JM, et al. HOXC4, HOXC5, and HOXC6 expression in non-Hodgkin's lymphoma: preferential expression of the HOXC5 gene in primary cutaneous anaplastic T-cell and oro-gastrointestinal tract mucosa-associated B-cell lymphomas. Blood. 1997;90(10):4116-4125.
327. Braun FK, Hirsch B, Al-Yacoub N et al. Resistance of cutaneous anaplastic large-cell lymphoma cells to apoptosis by death ligands is enhanced by CD30-mediated overexpression of c-FLIP. J Invest Dermatol. 2010,130(3): 826-840.
328. Paulli M, Berti E, Boveri E et al. Cutaneous CD30+ lymphoproliferative disorders: expression of BCL-2 and proteins of the tumor necrosis factor receptor superfamily. Hum Pathol. 1998;29(11):1223-1230.
329. Klemke CD, Brenner D, Weiss EM et al. Lack of T-cell receptor-induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-cell lymphoma cells from activation-induced cell death. Cancer Res. 2009;69(10): 4175-4183.
330. Mori M, Manuelli C, Pimpinelli N et al. CD30-CD30 ligand interaction in primary cutaneous CD30(+1 T-cell lymphomas: A clue to the pathophysiology of clinical regression. Blood. 1999;94(9):3077-3083.
331. Greisser J, Doebbeling U, Roos M et al. Apoptosis in CD30-positive lymphoproliferative disorders of the skin, fxp Dermatol. 2005;14(5):380-385.
332. Knol AC, Ehst BD, Dompmartin A et al. Toll-like receptor 2, 4, 7 and 9 expression in primary cutaneous CD30+ T-cell lymphoma. Br J Dermatol. 2009; 161(6):1414-1416.
333. Gelman AE, Zhang J, Choi Y, Turka LA. Toll-like receptor ligands directly promote activated CD4+ T cell survival. ) Immunol. 2004;172(10):6065-6073.
334. Bendigs S, Salzer U, Lipford GB, Wagner H, Heeg K. CpG- oligodeoxynucleotides co-stimulate primary T-cells in the absence of antigen-presenting cells. Eur J Immunol. 1999;29(4):1209-1218.
335. Ross CW, Schlegelmilch JA, Grogan TM, Weiss LM, Schnitzer B, Hanson CA. Detection of Epstein-Barr virus genome in Ki-1 (CD30)-positive, large-cell anaplastic lymphomas using the polymerase chain reaction. Am J Pathol. 1992; 141(2):457-465.
336. Herling M, Rassidakis GZ, Jones D, Schmitt-Graeff A, Sarris AH, Medeiros LJ. Absence of Epstein-Barr virus in anaplastic large cell lymphoma: a study of 64 cases classified according to World Health Organization criteria. Hum Pathol. 2004;35(4):455-459.
337. Lopategui JR, Gaffey MJ, Chan JK, et al. Infrequent association of EpsteinBarr virus with CD30-positive anaplastic large cell lymphomas from American and Asian patients. Am J Surg Pathol. 1995;19(1):42-49.
338. Nakagawa A, Nakamura S, lto M, Shiota M, Mori S, Suchi T. CD30-positive anaplastic large cell lymphoma in childhood: expression of p80npm/alk and absence of Epstein-Barr virus. Mod Pathol. 1997;10(3):210-215.
339. Feldman AL, Law M, Remstein ED, et al. Recurrent translocations involving the IRF4 oncogene locus In peripheral T-cell lymphomas. Leukemia. 2009;23(3):574-580.
340. Boni R, Xin H, Kamarashev J, et al. Allelic deletion at 9p21 -22 in primary cutaneous CD30(+1 large cell lymphoma. J Invest Dermatol. 2000,115(6):1104-1107.
341. Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker S. Genetic alterations in primary cutaneous CD30+ anaplastic large cell lymphoma. Genes Chromosomes Cancer. 2003;37(2):176-185.
342. Prochazkova M, Chevret E, Beylot-Barry M, et al. Chromosomal imbalances: a hallmark of tumour relapse in primary cutaneous CD30+ T-cell lymphoma. J Pathol. 2003;201(3):421-429.
343. Fischer TC, Gellrich S, Muche JM, et al. Genomic aberrations and survival in cutaneous T-cell lymphomas. J Invest Dermatol. 2004;122(3):579-586.
344. van Kester MS, Tensen CP, Vermeer MH, et al. Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators. J Invest Dermatol. 2010;130(2):563-575.
345. Wozniak MB, Piris MA. Cutaneous T-cell lymphoma: two faces of the same coin. J Invest Dermatol. 2010;130(2):348-351.
346. Mao X, Orchard G, Lillington DM, et al. BCL2 and JUNB abnormalities in primary cutaneous lymphomas. Br J Dermatol. 2004,151(3):546-556.
347. Franchina M, Kadin ME, Abraham LJ. Polymorphism of the CD30 promoter microsatellite repressive element is associated with development of primary cutaneous lymphoproliferative disorders. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1322-1325.
348. Li R, Morris SW. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev. 2008;28(3):372-412.
349. McDermott U, lafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008;68(9):3389-3395.
350. Lu L, Chose AK, Quail MR, et al. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors. Biochemistry. 2009;480(16):3600-3609.
351. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and cMet, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007;6(12, pt 1):3314-3322.
352. Bonvini P, Zorzi E, Mussolin L, et al. The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity. Haematologica. 2009;94(7):944-955.
353. Bartlett NL, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008;111(4):1848-1854.
354. Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010; 16(3):888-897.
355. Menzel C, Schirrmann T, Konthur Z, Jostock T, Dubel S. Human antibody RNase fusion protein targeting CD30+ lymphomas. Blood. 2008;111(7):3830-3837.
356. Drakos E, Atsaves V, Schlette E, et al. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53. Leukemia. 2009;23(12):2290-2299.
357. Sabbatini P, Korenchuk S, Rowand JL, et al. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2009;8(10):2811-2820.
358. Nasr MR, Laver JH, Chang M, Hutchison RE. Expression of anaplastic lymphoma kinase, tyrosine-phosphorylated STAT3, and associated factors in pediatric anaplastic large cell lymphoma: a report from the Children's Oncology Group. Am J Clin Pathol. 2007;127(5):770-778.
359. Pulford K, Falini B, Banham AH, et al. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood. 2000;96(4): 1605-1607.
360. Ait-Tahar K, Damm-Welk C, Burkhardt B, et al. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood. 2010;115(16):3314-3319.